Micafungina Macleods

Micafungin, the active ingredient in Micafungina Macleods, is an echinocandin antifungal presented as an intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of fungal infections in hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Macleods as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat serious fungal infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal Candida infection in the esophagus. - Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal infections in transplant recipients.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate stomach upset. - Elevated liver enzymes: mild increase in ALT/AST. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome. - Infusion-related reactions: hypotension or bronchospasm. - Renal impairment: acute kidney injury.

When using Micafungina Macleods, clinicians should observe several safety measures. - Monitor liver function: check ALT/AST before and during therapy. - Assess renal function: adjust use in patients with renal impairment. - Evaluate for hypersensitivity: discontinue if severe allergic reaction occurs. - Use cautiously in patients with pre‑existing cardiac disease: monitor hemodynamics during infusion. - Avoid concomitant use with strong CYP3A4 inducers: may reduce exposure. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce micafungin plasma levels. - Concurrent use with other echinocandins: increased risk of hepatotoxicity.

Moderate Interactions (Monitor Closely): - Cyclosporine: may increase micafungin exposure; monitor liver enzymes. - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity; assess liver function. - Warfarin: possible alteration of INR; check coagulation parameters.